NYSE:BIOLife Sciences
Bio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes
Bio-Rad Laboratories (NYSE:BIO) issued a cautious revenue outlook for 2026.
The company highlighted a material revenue impact tied to ongoing geopolitical disruptions in the Middle East.
Management reported progress on the Stilla acquisition, which is expected to be accretive within the year, and outlined business efficiency measures.
Bio-Rad enters this update with a mixed track record, with the share price at $280.12 and a 1 year return of 16.5% but a 3 year return of 39.4% and a 5 year...